(649 days)
Not Found
No
The device description and performance studies focus on the material properties and hemostatic efficacy of the polysaccharide particles, with no mention of AI or ML.
Yes
The device is used to achieve hemostasis and control bleeding, which are therapeutic actions.
No
Explanation: The device is a hemostat, intended to achieve hemostasis and control bleeding, not to diagnose a condition.
No
The device description explicitly states it is composed of "absorbable modified polymer (AMP®) particles," which are a physical substance, not software.
Based on the provided text, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use clearly states that the device is used to achieve hemostasis (stop bleeding) in emergency situations or for local management of bleeding. This is a direct therapeutic or procedural application on the body.
- Device Description: The description details the physical composition of the device (absorbable modified polymer particles) and its origin (plant starch). It does not describe a reagent, instrument, or system used to examine specimens from the human body.
- Lack of IVD Characteristics: There is no mention of analyzing samples (blood, urine, tissue, etc.) from the human body, providing diagnostic information, or being used in a laboratory setting.
IVDs are used to examine specimens from the human body to provide information for the diagnosis, prevention, monitoring, treatment, or alleviation of disease. This device's function is to directly interact with and control bleeding on the body's surface.
N/A
Intended Use / Indications for Use
RESPONDER® Polysaccharide Hemostat Rx is intended to be used to achieve hemostasis in emergency situations for the temporary control of severe topical bleeding.
RESPONDER® Polysaccharide Hemostat OTC is indicated for the local management of bleeding such as lacerations, minor cuts and abrasions.
Product codes
QSY
Device Description
RESPONDER® Polysaccharide Hemostat (RESPONDER®) is a medical device composed of absorbable modified polymer (AMP®) particles. AMP® particles are biocompatible, non-pyrogenic and derived from plant starch. The device contains no human or animal components.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies
Animal studies have also been conducted to support substantial equivalence claims of our product as compared to the predicate device CELOX Topical Hemostatic Granules. The objective of this study is to validate the efficacy and safety of RESPONDER® Polysaccharide Hemostat (compared to the predicate device). The results demonstrated that the proposed device is as safe as the predicate device.
Key Metrics
Not Found
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
N/A
0
Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. To the right of the blue square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue.
December 4, 2023
Starch Medical, Inc. Alice Li RA project manager 2150 Ringwood Ave. San Jose, California 95131
Re: K220525
Trade/Device Name: RESPONDER Polysaccharide Hemostat Regulatory Class: Not Classified Product Code: QSY Dated: December 7, 2022 Received: December 7, 2022
Dear Alice Li:
We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device" (https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download).
Your device is also subject to, among other requirements, the Quality System (QS) regulation (21 CFR Part 820), which includes, but is not limited to, 21 CFR 820.30, Design controls; 21 CFR 820.90, Nonconforming
1
product; and 21 CFR 820.100, Corrective and preventive action. Please note that regardless of whether a change requires premarket review, the QS regulation requires device manufacturers to review and approve changes to device design and production (21 CFR 820.30 and 21 CFR 820.70) and document changes and approvals in the device master record (21 CFR 820.181).
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products): good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely.
David Krause -S
for Yu-Chieh Chiu. Ph.D. Assistant Director DHT4B: Division of Infection Control and Plastic and Reconstructive Surgery Devices OHT4: Office of Surgical and Infection Control Devices Office of Product Evaluation and Ouality Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known) K220525
Device Name
RESPONDER® Polysaccharide Hemostat
Indications for Use (Describe)
RESPONDER® Polysaccharide Hemostat Rx is intended to be used to achieve hemostasis in emergency situations for the temporary control of severe topical bleeding.
RESPONDER® Polysaccharide Hemostat OTC is indicated for the local management of bleeding such as lacerations, minor cuts and abrasions.
Type of Use (Select one or both, as applicable)
Prescription Use (Part 21 CFR 801 Subpart D)
X Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
510(k) Summary
[As required by 21 CFR 807.92]
1. Submitter's Information
| Name of Sponsor: | Starch Medical Inc. |
|---|---|
| Address: | 2150 Ringwood Avenue San Jose California USA |
| Contact Name: | Alice Li |
| Telephone No.: | 408-428-9818 |
| Fax No.: | 408-383-9189 |
| Email Address: | alice@starchmedical.com |
2. Correspondent's Information
| Company Name: | Starch Medical Inc. |
|---|---|
| Correspondent Name: | Alice Li |
| Telephone No.: | 408-428-9818 |
| Email Address: | alice@starchmedical.com |
3. Trade Name, Common Name, Classification
| Trade Name: | RESPONDER® |
|---|---|
| Device Name: | Responder® Polysaccharide Hemostat |
| Mode Name: | RP0010/RP0025 |
| Regulation Classification: | Unclassified |
| Product Code: | QSY |
| Classification Panel: | General and Plastic Surgery |
Device Class:
4. Identification of Predicate Device(s)
The identified predicates within this submission are as follows:
The CELOX Topical Hemostatic Granules has been cleared by FDA through 510(k) No. K061079 (Decision Date – June 2, 2006).
4
5. Description of the Device
RESPONDER® Polysaccharide Hemostat (RESPONDER®) is a medical device composed of absorbable modified polymer (AMP®) particles. AMP® particles are biocompatible, non-pyrogenic and derived from plant starch. The device contains no human or animal components.
6. Intended Use/Indication for Use
-
RESPONDER® Polysaccharide Hemostat is intended to be used to achieve hemostasis in emergency situations for the temporary control of severe topical bleeding.
-
RESPONDER® Polysaccharide Hemostat OTC is indicated for the local management of bleeding such as minor lacerations, minor cuts and minor abrasions.
7. Technological Characteristics
The working situation and environment of RESPONDER® Polysaccharide Hemostat is the same as that of CELOX Topical Hemostatic Granules K061079, the technological characteristics of this product is designed to make same as that of the equivalence product.
The subject device has the same physical structure (Granules). same packaging (Foil Pouch) and same shelf life as that of the predicate. Both of the devices can achieve hemostasis by forming a gel barrier.
8. Performance
The RESPONDER® Polysaccharide Hemostat has taken the bio-compatibility, sterility and performance testing into concern in accordance to Food and Drug Administration related guidance and recognized international standards.
And although the sterilization methods are different, the Sterility Assurance Level (SAL) of 10° is achieved. The difference of sterilization method from predicate device does not affect the safety and performance of the device.
The bio-compatibility tests (ISO10993-5:2009. ISO10993-6:2016, ISO10993-10:2010. ISO 10993-11:2017. ASTM F756-17. USP41 NF36) in accordance to Food and Druq Administration related quidance and recognized international standards, indicated that RESPONDER® Polysaccharide Hemostat is bio-compatible and safe for its intended use.
Animal studies have also been conducted to support substantial equivalence claims of our product as compared to the predicate device CELOX Topical Hemostatic Granules. The objective of this study is to validate the efficacy and safety of RESPONDER® Polysaccharide Hemostat (compared to the predicate device). The results demonstrated that the proposed device is as safe as the predicate device.
9. Conclusion
5
In accordance with the Federal Food, Drug and Cosmetic Act, 21 CFR Part 807 and based on the information provided in this premarket notification, Starch Medical Inc. concludes that RESPONDER® Polysaccharide Hemostat is substantially equivalent to predicate devices with regard to safety and performance.